The project has recently been awarded a public grant via the French Norwegian Foundation funded by the foundation, the French Ministry of Research and the French Innovation Society. The project has also obtained Eureka status, which is a European quality label and prerequisite for obtaining French public support on industrial projects.
Emmanuel Blanc, R&D director of EDAP, said: “We are excited to work in conjunction with Epitarget and Inserm on this research project. In addition, we are confident that the use of our patented HIFU technology can be utilized to precisely deliver drugs encapsulated within liposomes to deep seated tumors while facilitating drug absorption by the cancerous cells.”